Literature DB >> 24946097

Verification of a Parkinson's disease protein signature in T-lymphocytes by multiple reaction monitoring.

Tiziana Alberio1, Kelly McMahon, Manuela Cuccurullo, Lee A Gethings, Craig Lawless, Maurizio Zibetti, Leonardo Lopiano, Johannes P C Vissers, Mauro Fasano.   

Abstract

Diagnosis of Parkinson's disease, the second most common neurodegenerative disease, is based on the appearance of motor symptoms. A panel of protein biomarkers in the T-lymphocyte proteome was previously proposed as a Parkinson's disease signature. Here, we designed an LC-MS based method to quantitatively evaluate this protein signature by multiple reaction monitoring (MRM) in T-lymphocytes and peripheral blood mononuclear cells from a new cohort of nine patients with Parkinson's disease and nine unaffected subjects. Patients were classified using the discriminant function obtained from two-dimensional electrophoresis and protein amounts measured by MRM, thus assigning seven controls out of nine as true negatives and nine patients out of nine as true positives. A good discriminant power was obtained by selecting a subset of peptides from the protein signature, with an area under the receiver operating characteristic curve of 0.877. A similar result is achieved by evaluating all peptides of a selected panel of proteins (gelsolin, moesin, septin-6, twinfilin-2, lymphocyte-specific protein 1, vimentin, transaldolase), with an area under the curve of 0.840. Conversely, the signature was not able to classify the enrolled subjects when evaluated in whole mononuclear cells. Overall, this report shows the portability of the proposed method to a large-scale clinical validation study.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24946097     DOI: 10.1021/pr401142p

Source DB:  PubMed          Journal:  J Proteome Res        ISSN: 1535-3893            Impact factor:   4.466


  6 in total

Review 1.  Mass spectrometry: A platform for biomarker discovery and validation for Alzheimer's and Parkinson's diseases.

Authors:  Eugene M Cilento; Lorrain Jin; Tessandra Stewart; Min Shi; Lifu Sheng; Jing Zhang
Journal:  J Neurochem       Date:  2019-01-31       Impact factor: 5.372

Review 2.  Role of α-synuclein in inducing innate and adaptive immunity in Parkinson disease.

Authors:  Heather E Allen Reish; David G Standaert
Journal:  J Parkinsons Dis       Date:  2015       Impact factor: 5.568

Review 3.  Advances in targeted proteomics and applications to biomedical research.

Authors:  Tujin Shi; Ehwang Song; Song Nie; Karin D Rodland; Tao Liu; Wei-Jun Qian; Richard D Smith
Journal:  Proteomics       Date:  2016-08       Impact factor: 3.984

4.  Epigenetic DNA Methylation Profiling with MSRE: A Quantitative NGS Approach Using a Parkinson's Disease Test Case.

Authors:  Adam G Marsh; Matthew T Cottrell; Morton F Goldman
Journal:  Front Genet       Date:  2016-11-02       Impact factor: 4.599

5.  COPD Exacerbation Biomarkers Validated Using Multiple Reaction Monitoring Mass Spectrometry.

Authors:  Janice M Leung; Virginia Chen; Zsuzsanna Hollander; Darlene Dai; Scott J Tebbutt; Shawn D Aaron; Kathy L Vandemheen; Stephen I Rennard; J Mark FitzGerald; Prescott G Woodruff; Stephen C Lazarus; John E Connett; Harvey O Coxson; Bruce Miller; Christoph Borchers; Bruce M McManus; Raymond T Ng; Don D Sin
Journal:  PLoS One       Date:  2016-08-15       Impact factor: 3.240

Review 6.  Recent Evidence in Epigenomics and Proteomics Biomarkers for Early and Minimally Invasive Diagnosis of Alzheimer's and Parkinson's Diseases.

Authors:  Sonia Mayo; Julián Benito-León; Carmen Peña-Bautista; Miguel Baquero; Consuelo Cháfer-Pericás
Journal:  Curr Neuropharmacol       Date:  2021       Impact factor: 7.363

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.